Here's more info from a different article, about how the CRO Forteo seemingly totally pulled an Amarex. Golly,why would giving some patients placebo instead of the drug screw up the results? Clearly Acelyrin is just making excuses for their placebo... I mean, their drug...... failing to work. /s

Quote:

---

The PsA trial had four arms: 160 mg weekly; 160 mg every other week; 80 mg every four weeks; and the placebo group. Acelyrin apparently provided the correct protocol with the outlined dosing sequences. However, the biotech claimed that information was programmed incorrectly by a vendor working with Fortrea. This error was not identified by the CRO’s testing processes, according to Acelyrin.

It meant that some patients in the group receiving a 160 mg dose every other week as well as some of those in the 80 mg cohort received placebo and active treatment in random order rather than alternating as intended.

Acelyrin said there was no risk to patients due to the error and no one received more active ingredients than the protocol had allowed for.

The error has now been addressed and the dosing sequence fixed. Acelyrin has no reason to believe the other arms of the trial were in any way affected. But the company is still figuring out the implications of the sequencing errors on the trial groups that did receive the wrong dosing.

Acelyrin pledged to never use Fortrea for any new trials it plans to conduct.

https://www.fiercebiotech.com/biotech/acelyri...ipo-market

---